Anwesha Dey

Anwesha Dey


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
ADAnwesha Dey
Anwesha Dey
XVXaralabos Varelas
Xaralabos Varelas
KGKun-Liang Guan
Kun-Liang Guan

1 May 2019 in Trends in Cancer
Verified
Journal Article
Open access
PCPhilamer C. Calses
Philamer C. Calses
JCJames J. Crawford
James J. Crawford
JLJennie R. Lill
Jennie R. Lill
ADAnwesha Dey
Anwesha Dey
The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.

5 June 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
THThijs J. Hagenbeek
Thijs J. Hagenbeek
JZJason R. Zbieg
Jason R. Zbieg
MHMarc Hafner
Marc Hafner
RMRana Mroue
Rana Mroue
JLJennifer A. Lacap
Jennifer A. Lacap
ADAnwesha Dey
Anwesha Dey
The Hippo pathway is a key growth control pathway that is conserved across species. The downstream effectors of the Hippo pathway, YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), are frequently activated in cancers to drive proliferation and survival. Based on the premise that sustained interactions between YAP/TAZ and TEADs (transcriptional enhanced associate domain) are central to their transcriptional activities, we discovered a potent small-molecule inhibitor (SMI), GNE-7883, that allosterically blocks the interactions between YAP/TAZ and all human TEAD paralogs through binding to the TEAD lipid pocket. GNE-7883 effectively reduces chromatin accessibility specifically at TEAD motifs, suppresses cell proliferation in a variety of cell line models and achieves strong antitumor efficacy in vivo. Furthermore, we uncovered that GNE-7883 effectively overcomes both intrinsic and acquired resistance to KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C inhibitors in diverse preclinical models through the inhibition of YAP/TAZ activation. Taken together, this work demonstrates the activities of TEAD SMIs in YAP/TAZ-dependent cancers and highlights their potential broad applications in precision oncology and therapy resistance.

20 September 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KSKyung W. Song
Kyung W. Song
KEKyle A. Edgar
Kyle A. Edgar
EHEmily J. Hanan
Emily J. Hanan
MHMarc Hafner
Marc Hafner
JOJason Oeh
Jason Oeh
LFLori S. Friedman
Lori S. Friedman
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity and a manageable safety profile in patients with PIK3CA-mutant breast cancer. However, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent mutant p110a degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression. This study establishes a new strategy for identifying inhibitors that specifically target mutant tumors by selective degradation of the mutant oncoprotein and provide a strong rationale for pursuing PI3Kα degraders in patients with HER2-positive breast cancer. Significance: The PI3K inhibitors GDC-0077 and taselisib have a unique mechanism of action; both inhibitors lead to degradation of mutant p110a protein. The inhibitors that have the ability to trigger specific degradation of mutant p110a without significant change in wild-type p110a protein may result in improved therapeutic index in PIK3CA-mutant tumors. See related commentary by Vanhaesebroeck et al., p. 20. This article is highlighted in the In This Issue feature, p. 1

19 April 2019 in Science
Verified
Journal Article
Closed access
MHMeng He
Meng He
MCMira S. Chaurushiya
Mira S. Chaurushiya
JWJoshua D. Webster
Joshua D. Webster
SKSarah Kummerfeld
Sarah Kummerfeld
RRRohit Reja
Rohit Reja
VDVishva m Dixit
Vishva m Dixit
Tissue specificity of tumor suppression: It is well known that the loss of tumor suppressor genes leads to a limited subset of cancers in specific tissues. But why just those tissues? He et al. found a relatively simple explanation for how this tissue selectivity works for the tumor suppressor BAP1 using a mouse model of BAP1-induced cancer. In most cells, loss of BAP1 caused cell death or apoptosis. But in the tissues that formed tumors, differences in the regulation of genes with antiapoptotic effects allowed the cells to survive, even though BAP1 was lost. At least for this one tumor suppressor, its inactivation would normally cause a cell to die; however, this mechanism is absent in a subset of tissues, allowing the cells to proliferate and cause a tumor. Science , this issue p. 283

11 September 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
THThijs J. Hagenbeek
Thijs J. Hagenbeek
JWJoshua D. Webster
Joshua D. Webster
NKNoelyn M. Kljavin
Noelyn M. Kljavin
MCMatthew T. Chang
Matthew T. Chang
TPTrang Pham
Trang Pham
ADAnwesha Dey
Anwesha Dey
Transcriptional cofactors YAP and TAZ have distinct roles in promoting proinflammatory cytokine production and tumorigenesis.